Women’s Gymnastics | January 11
KENT, Oh. – Freshman Avery Riiff tied for the win on beam…
From Marilyn Monroe’s sequined V-neck dress to Lady Gaga’s periwinkle ballgown, the Golden Globes have delivered their fair share of glamour, sparkle and show-stopping outfits over the years.
Sunday should be no different, with the stars of…
300 new homes have now been built in remote First Nations communities and town camps across the Northern Territory, marking a major milestone in the Australian and Northern Territory Governments’ remote housing partnership.
The joint $4 billion investment aims to halve overcrowding for First Nations families by delivering up to 2,700 new homes by mid-2034.
The 300th home was recently completed in Peppimenarti. The four bedroom, two-bathroom house was built through a joint venture between Green River Aboriginal Corporation and Big River Housing.
This milestone follows new homes being built in remote communities including Ampilatwatja, Maningrida, Mutitjulu, Ramingining and Lajamanu.
The Northern Territory Remote Housing Package is being delivered under a partnership between the Albanese and Finnochiaro Governments, Aboriginal Housing Northern Territory and the four Northern Territory Land Councils.
Shared decision-making through the Partnership Agreement ensures First Nations organisations are central to implementing this significant investment.
Improving housing is a key part of Closing the Gap, supporting First Nations families and building a foundation for healthier, stronger communities.
Since its launch on 1 July 2024, the Northern Territory Remote Housing Package has generated significant economic benefits, creating jobs during construction, supporting employment and upskilling local trades while boosting businesses and suppliers across the Territory.
Quotes attributable to Minister for Indigenous Australians, Senator Malarndirri McCarthy:
“These 300 new homes are part of our long-term plan to ease overcrowding and improve living conditions in remote Northern Territory communities.
“This investment is not only changing the lives of First Nations families, it is building a stronger future for remote communities while at the same creating jobs, building skills and backing Territory businesses.
“We will continue to work with the Northern Territory Government, Aboriginal Housing Northern Territory and Land Councils to ensure remote housing solutions are community-led and sustainable for the long term.”
Quotes attributable to Special Envoy for Remote Communities, Marion Scrymgour:
“Our government is taking real action to address overcrowding in remote Territory communities by investing $2 billion to build 2,700 homes across the bush.
“These 300 new homes showcase what can be achieved when all levels of government work with local stakeholders to deliver for people in remote communities.
“Building these homes will not only impact living conditions but will also deliver vital employment opportunities to some of our most economically disadvantaged communities.”
Quotes attributable to Northern Territory Minister for Housing, Steve Edgington:
“As part of the Finocchiaro Government’s year of action, certainty and security, we’re proud to be delivering more homes for families in remote locations right across the Territory.
“Everyone knows that improvements in housing contributes to better health, education and employment outcomes for families and I am delighted to have reached the completion of 300 new homes in the bush.
“It’s pleasing to see the latest joint venture between Green River Aboriginal Corporation and Big River Housing achieved an Aboriginal employment rate of nearly 40%, including two apprentices and two local Aboriginal employees.
“Our government is delivering for the bush by providing safe, modern and practical spaces for families to thrive.”
Nicklas Backstrom’s remaining ties to the Washington DC area have ended with the sale of his home.
Backstrom’s Northern Virginia mansion was purchased by an undisclosed buyer for $11 million last week, after being put on the market…
Goodbye blonde (at least for now). Lisa surprised fans with a new dark hair color the day before the 83rd Golden Globes: dark chocolate. The White Lotus star, who is set to present at tonight’s festivities, which is taking place at the Beverly…
MINNEAPOLIS – The University of Minnesota women’s basketball team (12-4, 3-2 Big Ten) rallied back from a 13-point deficit to defeat the No. 21 ranked USC Trojans (10-6, 2-3 Big Ten) 63-62 at home Sunday.
The Golden Gophers had two players…
Richard Francis, Teva’s President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)
TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva’s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company’s milestones achieved in 2025, transformative initiatives, and forward-looking outlook for 2026 and beyond.
Presentation Highlights:
Expected 2025 Performance
|
$ billions, except EPS or as noted |
2025 Outlook |
Expected 2025 performance relative to Outlook (excluding duvakitug milestones) |
Additional contribution from expected duvakitug milestones |
|
Revenues* |
$16.8 – $17.0 |
Lower point of the range |
$500M |
|
Operating Margin |
~26.2% – 27.1% |
Mid to high point of the range |
~80%-85% |
|
Adjusted EBITDA |
$4.8 – $5.0 |
Midpoint of the range |
~$400M-$430M |
|
Tax Rate |
15%-18% |
Lower point of the range |
|
|
Diluted EPS ($) |
2.55 – 2.65 |
Higher point of the range |
|
|
Free Cash Flow** |
$1.6 – $1.9 |
Higher point of the range |
~$500M |
|
Net leverage |
~2.5x – 2.9x |
Midpoint of the range |
~2.5x |
Path to achieving 2027 targets and additional 2030 targets
|
$billionsor as noted |
2026 |
2027 |
2030 |
|
Revenues* |
Flat to slightly down vs. 2025 |
Low-single digit growth |
Mid-single digit CAGR |
|
Operating Profit |
Growing vs. 2025 |
30% |
>30% |
|
Adjusted EBITDA |
Growing vs. 2026 |
Growing |
|
|
Free Cash Flow** |
Growing vs. 2025 |
>$2.7 |
>$3.5 |
|
Net Leverage |
~2.0-2.2x |
<2x |
<2x |
|
Cumulative Transformation Programs Savings |
~$450M-500M |
~$700M |
Note: 2026 commentary compared to 2025 results excluding duvakitug milestones, except for net debt leverage calculation.
* Revenues presented on a GAAP basis; all other metrics presented on a non-GAAP basis.
** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.
To access a live webcast of the presentation, visit Teva’s Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to better health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures as defined by SEC rules. Management believes that such non-GAAP financial measures provide useful information to investors to facilitate their understanding of our business because the non-GAAP financial measures are used by Teva’s management and board of directors, in conjunction with other performance metrics, to evaluate the operational performance of the company, to compare against the company’s work plans and budgets, and ultimately to evaluate the performance of management; the company’s annual budgets are prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. Investors should consider the non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. In the case of the non-GAAP financial measures disclosed in this press release, we are not providing comparable forward looking guidance for GAAP financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.
Teva Cautionary Note Regarding Forward Looking Statements
This Press Release and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “outlook” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this document, in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned “Risk Factors” and “Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
TL;DR: Stop paying for separate AI tools and grab a 1min.AI lifetime subscription for $74.97 for a limited time only.
Juggling separate subscriptions for chat tools, image generators,…
Special clinics set up at district, tehsil levels to provide free tests, treatment
…